Hims & Hers Health, Inc. (NYSE:HIMS) COO Melissa Baird Sells 11,750 Shares

Hims & Hers Health, Inc. (NYSE:HIMS) COO Melissa Baird sold 11,750 shares of the business’s stock in a transaction that occurred on Thursday, May 2nd. The stock was sold at an average price of $12.08, for a total transaction of $141,940.00. Following the sale, the chief operating officer now owns 538,932 shares of the company’s stock, valued at approximately $6,510,298.56. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Melissa Baird also recently made the following trade(s):

• On Monday, April 8th, Melissa Baird sold 11,751 shares of Hims & Hers Health stock. The stock was sold at an average price of $14.74, for a total value of $173,209.74.
• On Friday, April 5th, Melissa Baird sold 11,751 shares of Hims & Hers Health stock. The shares were sold at an average price of $14.58, for a total value of $171,329.58.
• On Wednesday, March 6th, Melissa Baird sold 11,751 shares of Hims & Hers Health stock. The shares were sold at an average price of $13.99, for a total transaction of $164,396.49.

Hims & Hers Health Stock Down 8.1 %

Shares of HIMS stock opened at $11.25 on Friday. The stock has a market cap of $2.41 billion, a P/E ratio of -102.27 and a beta of 0.97. Hims & Hers Health, Inc. has a fifty-two week low of $5.65 and a fifty-two week high of $17.16. The business has a fifty day simple moving average of $14.01 and a 200-day simple moving average of $10.25.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings data on Monday, February 26th. The company reported $0.01 EPS for the quarter, beating analysts’ consensus estimates of ($0.02) by $0.03. The firm had revenue of $246.60 million for the quarter, compared to analysts’ expectations of $245.84 million. Hims & Hers Health had a negative net margin of 2.70% and a negative return on equity of 7.21%. The firm’s revenue was up 47.4% on a year-over-year basis. During the same period in the prior year, the company earned ($0.05) EPS. On average, sell-side analysts anticipate that Hims & Hers Health, Inc. will post 0.11 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. FNY Investment Advisers LLC acquired a new stake in shares of Hims & Hers Health during the 4th quarter worth about $48,000. Belpointe Asset Management LLC purchased a new stake in shares of Hims & Hers Health in the third quarter valued at $76,000. EMC Capital Management grew its position in shares of Hims & Hers Health by 80.0% in the third quarter. EMC Capital Management now owns 12,000 shares of the company’s stock valued at $79,000 after purchasing an additional 5,332 shares during the period. Certuity LLC acquired a new position in Hims & Hers Health in the fourth quarter valued at $109,000. Finally, Corton Capital Inc. purchased a new position in Hims & Hers Health during the third quarter worth about $122,000. 63.52% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on HIMS shares. Tigress Financial increased their price objective on Hims & Hers Health from $14.00 to $15.00 and gave the stock a “buy” rating in a research report on Friday, January 5th. Leerink Partnrs reissued a “market perform” rating on shares of Hims & Hers Health in a research note on Monday, February 26th. TheStreet raised shares of Hims & Hers Health from a “d” rating to a “c” rating in a report on Monday, March 4th. Guggenheim lifted their price objective on Hims & Hers Health from $15.00 to $17.00 and gave the company a “buy” rating in a report on Tuesday, February 27th. Finally, Truist Financial raised their price target on Hims & Hers Health from $10.00 to $13.00 and gave the company a “hold” rating in a report on Tuesday, February 27th. Five investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $14.85.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.